TY  - JOUR 
AU  - López-Borrego, S.
AU  - Campos-Silva, C.
AU  - Sandúa, A.
AU  - Camino Martinez, Tamara
AU  - Téllez-Pérez, L.
AU  - Alegre, E.
AU  - Beneitez, A.
AU  - Jara-Acevedo, R.
AU  - Paschen, A.
AU  - Pardo, M.
AU  - González, Á.
AU  - Valés-Gómez, M.
PY  - 2023
SN  - 2296-634X
UR  - http://hdl.handle.net/20.500.11940/21715
AB  - Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK...
LA  - eng
TI  - MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated
DO  - 10.3389/fcell.2022.1055288
T2  - Frontiers in Cell and Developmental Biology
KW  - AS Santiago
KW  - IDIS
VL  - 10
ER  -